Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period

Pretransplantation anti-major histocompatibility complex class I chain-related molecule A (MICA) sensitization is an uncommon event and its role on kidney graft evolution is not completely defined. A retrospective study of patients transplanted between 2005 and 2011 in our center (n=727) was perform...

Full description

Saved in:
Bibliographic Details
Published inTransplantation Vol. 96; no. 1; p. 70
Main Authors Sánchez-Zapardiel, Elena, Castro-Panete, María J, Castillo-Rama, Marcela, Morales, Pablo, Lora-Pablos, David, Valero-Hervás, Diana, Ruiz-García, Raquel, Apaza, Jacqueline, Talayero, Paloma, Andrés, Amado, Morales, José M, Paz-Artal, Estela
Format Journal Article
LanguageEnglish
Published United States 15.07.2013
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Pretransplantation anti-major histocompatibility complex class I chain-related molecule A (MICA) sensitization is an uncommon event and its role on kidney graft evolution is not completely defined. A retrospective study of patients transplanted between 2005 and 2011 in our center (n=727) was performed. Recipients were classified in four groups, according either to multiplexed flow cytometry-recorded anti-human leukocyte antigen (HLA) and anti-MICA antibodies or to percent panel-reactive antibody (PRA; by complement-dependent cytotoxicity) and anti-MICA antibodies. In the total cohort, 52 (7.15%) patients had preformed anti-MICA antibodies, and these were not related with anti-HLA, previous transplantations, or recipient female sex (potential pregnancies). Kaplan-Meier curves showed global allograft survival differences (P=0.042) mostly due to pronounced decrease in PRA+MICA+ group early after transplantation. Biopsy-proven allograft rejection rate increased after month 12 in PRA+MICA- group and was higher early after transplantation in PRA+MICA+ group (P=0.033). In paired comparisons, rejection incidence was superior in PRA+MICA- versus PRA-MICA- patients (17% vs. 7%; P=0.007) at 24 months, confirming the widely reported deleterious effect of PRA+ status, but at 3 months rejection was higher in PRA+MICA+ versus PRA-MICA- patients (14% vs. 2%; P=0.009). Among patients categorized according anti-HLA and anti-MICA antibodies, the most striking difference in rejection was observed at 3 months (8% in HLA-MICA+ vs. 2% in HLA-MICA- patients; P=0.032). In the multivariate analysis, HLA-MICA+ status at 3 months independently conferred the highest risk for rejection (odds ratio, 5.07; P=0.049). Pretransplantation sensitization against MICA and HLA are independent events. Preformed anti-MICA antibodies independently increase risk for kidney rejection and enhance the deleterious effect of PRA+ status early after transplantation.
ISSN:1534-6080
DOI:10.1097/TP.0b013e3182943506